Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories senior vice president Eric Shroff reported two stock transactions involving Abbott common shares. On March 2, 2026, he completed an open-market sale of 709 shares at a price of $115.58 per share, leaving him with 39,164 directly held shares afterward.
On February 27, 2026, he disposed of 1,384 shares at $116.26 per share to cover tax withholding obligations, a non-market transaction typically linked to equity compensation. Both holdings are reported as direct ownership of common shares without par value.
Abbott Laboratories executive Christopher J. Scoggins reported a tax-related share disposition. On February 27, 2026, he had 4,997 common shares withheld at $116.26 per share in a tax-withholding disposition, classified under code F as payment of tax liability by delivering securities.
After this non-open-market transaction, Scoggins’ directly owned holdings in Abbott Laboratories common shares were reported as 77,126 shares.
Abbott Laboratories executive Daniel Gesua Sive Salvadori, EVP and Group President, reported two share transactions. On March 2, 2026, he executed an open-market sale of 885 common shares at $115.58 per share. On February 27, 2026, he disposed of 6,615 shares at $116.26 per share to satisfy tax-withholding obligations. Following these transactions, he directly holds 146,377 Abbott common shares.
Abbott Laboratories executive Louis H. Morrone reported selling 1,144 common shares in an open‑market transaction at $115.58 per share on March 2, 2026. After this sale, his directly held stake was 76,843 common shares.
On February 27, 2026, 4,040 common shares were disposed of at $116.26 per share to cover tax withholding obligations rather than as an open‑market sale. The filing also notes 12 common shares held indirectly through a Profit Sharing Trust as of February 27, 2026.
ABBOTT LABORATORIES Executive Vice President Mary K. Moreland reported insider share transactions. On March 2, 2026, she completed an open-market sale of 613 common shares at $115.58 per share. On February 27, 2026, 4,630 common shares were disposed of at $116.26 per share to cover tax liabilities by delivering shares.
After these transactions, her directly held common shares totaled 104,291. In addition, 11,845 common shares were held indirectly through a Profit Sharing Trust, with that trust balance reported as of February 27, 2026.
Abbott Laboratories vice president and controller John A. McCoy Jr. reported multiple transactions in Abbott common shares. On March 2, 2026, he completed an open-market sale of 585 shares at $115.58 per share. On February 27, 2026, he disposed of 1,142 shares at $116.26 per share to cover tax obligations by delivering shares rather than cash. After these transactions, he held 24,628 common shares directly. A separate indirect holding of 58 shares was reported in a Profit Sharing Trust, with the balance noted as of February 27, 2026.
Abbott Laboratories Chairman and CEO Robert B. Ford reported a tax-related share disposition. On February 27, 2026, he disposed of 30,308 common shares at $116.26 per share through a tax-withholding transaction, a method used to satisfy tax obligations rather than an open-market sale.
After this transaction, Ford held 306,461 common shares directly. In addition, 216,203 common shares were held indirectly through the Ford Family Trust, where he serves as co-trustee, reflecting an additional layer of beneficial ownership separate from his direct holdings.
ABBOTT LABORATORIES executive Lisa D. Earnhardt, EVP and Group President, reported a tax-withholding disposition of 8,577 common shares on February 27, 2026. The shares were valued at $116.26 per share for tax purposes, and she held 90,407 shares directly after this transaction.
Abbott Laboratories executive Elizabeth C. Cushman reported two share dispositions. On March 2, she completed an open-market sale of 263 common shares at $115.58 per share, leaving her with 38,573 shares held directly.
On February 27, she disposed of 1,421 shares at $116.26 per share to cover tax obligations through a tax-withholding transaction, rather than a traditional sale. Both transactions involve Abbott common shares without par value and reflect routine insider activity by the company’s EVP, General Counsel and Secretary.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported a tax-related share disposition. On February 27, 2026, 7,441 common shares were surrendered at $116.26 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 71,172 common shares and indirectly held 366 shares through a Profit Sharing Trust as of that date.